Kailera Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Net Income	-148.96
Depreciation & Amortization	0.31
Stock-Based Compensation	10.94
Other Adjustments	0.71
Changes in Accounts Payable	4.69
Changes in Accrued Expenses	33.3
Changes in Other Operating Activities	-21.21
Operating Cash Flow	-120.21
Operating Cash Flow Growth	-
Capital Expenditures	-2.09
Purchases of Investments	-632.16
Proceeds from Sale of Investments	141.65
Investing Cash Flow	-492.6
Long-Term Debt Issued	100
Net Long-Term Debt Issued (Repaid)	100
Issuance of Common Stock	0.1
Net Common Stock Issued (Repurchased)	0.1
Issuance of Preferred Stock	498.87
Net Preferred Stock Issued (Repurchased)	498.87
Other Financing Activities	-0.32
Financing Cash Flow	598.66
Net Cash Flow	-14.15
Free Cash Flow	-122.3
Free Cash Flow Growth	-
Free Cash Flow Per Share	-778968.00
Levered Free Cash Flow	-33.95
Unlevered Free Cash Flow	-143.34

SEC Filings: 10-K · 10-Q